A New Era in the Treatment of Amyloidosis?
- 29 August 2013
- journal article
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 369 (9) , 866-868
Abstract
Amyloidosis is a diverse group of diseases caused by extracellular accumulation of protein in a highly ordered, abnormal, insoluble fibrillar form. These diseases can be hereditary or acquired and localized or systemic. Most are progressive and fatal. Among the almost 30 different proteins that have been found to form amyloid in humans, transthyretin, a carrier molecule of thyroxine and vitamin A, is of particular interest because it may cause both hereditary and acquired amyloidosis with a diverse range of symptoms. In addition, transthyretin amyloid may be more prevalent than previously thought, and several potential new treatments are on the horizon. . . .Keywords
This publication has 10 references indexed in Scilit:
- Safety and Efficacy of RNAi Therapy for Transthyretin AmyloidosisNew England Journal of Medicine, 2013
- AL Amyloid Imaging and Therapy with a Monoclonal Antibody to a Cryptic Epitope on Amyloid FibrilsPLOS ONE, 2012
- Recent advances in the treatment of familial amyloid polyneuropathyTherapeutic Advances in Neurological Disorders, 2012
- Liver transplantation and transthyretin amyloidosisMuscle & Nerve, 2012
- Tafamidis for transthyretin familial amyloid polyneuropathyNeurology, 2012
- Cardiac transthyretin amyloidosisHeart, 2012
- Clearance of extracellular misfolded proteins in systemic amyloidosis: Experience with transthyretinFEBS Letters, 2012
- The Diflunisal Trial: Study accrual and drug toleranceAmyloid, 2012
- Usefulness and limitations of 99mTc-3,3-diphosphono-1,2-propanodicarboxylic acid scintigraphy in the aetiological diagnosis of amyloidotic cardiomyopathyEuropean Journal of Nuclear Medicine and Molecular Imaging, 2010
- Antibodies to human serum amyloid P component eliminate visceral amyloid depositsNature, 2010